NCT-05280470

PHASE 2, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF DS-7300A, A B7-H3 ANTIBODY-DRUG-CONJUGATE (ADC), IN SUBJECTS WITH PRETREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC).

In this Phase 2 trial, which is conducted at multiple locations, researchers are investigating DS-7300A, a new treatment. This study focuses on individuals who have previously received treatment for extensive-stage small cell lung cancer (ES-SCLC). The goal is to evaluate the effectiveness and safety of DS-7300A in this patient population.

Phase 2 trial: An advanced point of testing, where they're trying to confirm if a treatment works well.

extensive-stage small cell lung cancer: Cancer which has spread from the lungs to other areas of the body

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05280470

Clinical Trial Site: Einstein

To see all available clinical trials click here.